Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis

American Journal of Respiratory and Critical Care Medicine

Volumn 168, Issue 8, 2003, Pages 918-951

  Gibson, Ronald L ^a   Burns, Jane L ^a   Ramsey, Bonnie W ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Airway disease; Antibiotics; Cystic fibrosis; Cystic fibrosis transmembrane conductance regulator; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; AMOXICILLIN; AZITHROMYCIN; AZTREONAM; CEFALEXIN; CEFAZOLIN; CEFPODOXIME PROXETIL; CEFPROZIL; CEFTAZIDIME; CEFUROXIME AXETIL; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; CLAVULANIC ACID; CLINDAMYCIN; COLISTIN; DICLOXACILLIN; ERYTHROMYCIN; IMIPENEM; MEROPENEM; MINOCYCLINE; NAFCILLIN; PIPERACILLIN; SULFAMETHOXAZOLE; TICARCILLIN; TOBRAMYCIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; TRIMETHOPRIM; UNINDEXED DRUG; VANCOMYCIN;

ACHROMOBACTER; ACHROMOBACTER XYLOSOXIDANS; AIRWAY; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIUM ADHERENCE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; BIOLOGICAL MONITORING; BURKHOLDERIA CEPACIA; CHILD CARE; CHRONIC DISEASE; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; CYSTIC FIBROSIS; DIAGNOSTIC PROCEDURE; DISEASE EXACERBATION; DISEASE TRANSMISSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; EPITHELIUM CELL; ERADICATION THERAPY; GENOTYPE; GRAM NEGATIVE INFECTION; HAEMOPHILUS INFLUENZAE; HEALTH CARE; HEALTH CARE POLICY; HEALTH STATUS; HUMAN; HYDRATION; IMMUNITY; IMMUNOTHERAPY; INFECTION CONTROL; INFECTION PREVENTION; LABORATORY TEST; LUNG CLEARANCE; LUNG FUNCTION TEST; LUNG INFECTION; MICROBIOLOGICAL EXAMINATION; MOLECULAR DYNAMICS; MUCOCILIARY CLEARANCE; MYCOBACTERIOSIS; MYCOBACTERIUM; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; PHLEBITIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STENOTROPHOMONAS MALTOPHILIA; THORAX RADIOGRAPHY; THROMBOCYTE DYSFUNCTION; TREATMENT OUTCOME;

ACHROMOBACTER; AMBULATORY CARE; BURKHOLDERIA CEPACIA; BURKHOLDERIA INFECTIONS; CHRONIC DISEASE; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DRUG RESISTANCE, BACTERIAL; GENE TRANSFER TECHNIQUES; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INFECTION CONTROL; MUCOCILIARY CLEARANCE; MYCOBACTERIUM INFECTIONS, ATYPICAL; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; STENOTROPHOMONAS MALTOPHILIA; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 0142043977     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200304-505SO     Document Type: Review

References (490)

1. Davis PB, Drumm M, Konstan MW. Cystic fibrosis: state of the art. Am J Respir Crit Care Med 1996;154:1229-1256.
2. Welsh MJ, Ramsey BW, Accurso F, Cutting G. Cystic fibrosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular basis of inherited diseases, 8th ed. New York: McGraw-Hill; 2001. p. 5121-5188.
3. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok Si, Plasvic N, Chou J, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245:1066-1072.
4. Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, Buchwald M, Tsui LC. Identification of the cystic fibrosis gene: genetic analysis. Science 1989;245:1073-1080.
5. Rommens JM, Iannuzzi MC, Kerern B, Drumm ML, Melmer G, Dean M, Rozmahel R, Cole JL, Kennedy D, Hidaka N. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989; 245:1059-1065.
6. Cystic Fibrosis Foundation Patient Registry. 2001 Annual Data Report to the Center Directors. Bethesda, MD: Cystic Fibrosis Foundation; 2002.
7. Hamosh A, Fitz-Simmons SC, Macek M Jr, Knowles MR, Rosenstein BJ, Cutting GR. Comparison of the clinical manifestations of cystic fibrosis in black and white patients. J Pediatr 1998;132:255-259.
8. Grebe TA, Seltzer WK, DeMarchi J, Silva DK, Doane WW. Genetic analysis of Hispanic individuals with cystic fibrosis. Am J Med Genet 1994;54:443-446.
9. Imalzumi Y. Incidence and mortality rates of cystic fibrosis in Japan, 1969-1992. Am J Med Genet 1995;58:161-168.
10. Hill ID, Macdonald WB, Bowie MD. Cystic fibrosis in Cape Town. S Afr Med J 1988;73:147-149.
11. Zielenski J, Rozmahel R, Bozon D, Kerem B, Grzelczak Z, Riordan JR, Rommens J, Tsui LC. Genomic DNA sequence of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Genomics 1991; 10:214-228.
12. Anonymous. Cystic Fibrosis Genetic Analysis Consortium: population variation of common cystic fibrosis mutations. Hum Mutat 1994;4:167-177.
13. Anonymous. Cystic Fibrosis Genetic Analysis Consortium: worldwide survey of the delta F508 mutation-report from the Cystic Fibrosis Genetic Analysis Consortium (CFGAC). Am J Hum Genet 1990;47: 354-359.
14. Gabriel SE, Brigman KN, Koller BH, Boucher R, Stutts MJ. Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model. Science 1994;266:107-109.
15. Schroeder SA, Gaughan DM, Swift M. Protection against bronchial asthma by CFTR delta F508 mutation: a heterozygote advantage in cystic fibrosis. Nat Med 1995;1:703-705.
16. Kerem E, Kalman YM, Yahav Y, Shoshani T, Abeliovich D, Szeinberg A, Rivlin J, Blau H, Tal A, Ben-Tur L, et al. Highly variable incidence of cystic fibrosis and different mutation distribution among different Jewish ethnic groups in Israel. Hum Genet 1995;96:193-197.
17. Rozen R, Schwartz RH, Human BC, Stanislovitis P, Horn GT, Klinger K, Daigneault J, De Braekeleer M, Kerem B, Tsui L. Cystic fibrosis mutations in North American populations of French ancestry: analysis of Quebec French-Canadian and Louisiana Acadian families. Am J Hum Genet 1990;47:606-610.
18. Dork T, El-Harith EH, Stuhrmann M, Macek M Jr, Egan M, Cutting G, Tzetis M, Kanavakis E, Carles S, Claustres M, et al. Evidence for a common ethnic origin of cystic fibrosis mutation 3120+IG-A in diverse populations. Am J Hum Genet 1998;63:656.
19. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 1993;73:1251-1254.
20. Denning GM, Anderson MP, Amara JF, Marshall J, Smith AE, Welsh MJ. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 1992;358:761-764.
21. Anderson MP, Welsh MJ. Regulation by ATP and ADP of CFTR chloride channels that contain mutant nucleotide-binding domains. Science 1992;257:1701-1704.
22. Sheppard DN, Rich DP, Ostedgaard L, Gregory RJ, Smith A, Welsh MJ. Mutations in CFTR associated with mild-disease-form Cl-channels with altered pore properties. Nature 1993;362:160-164.
23. Highsmith WE, Burch LH, Zhou Z, Olsen JC, Boat TE, Spock A, Gorvoy JD, Quittel L, Friedman KJ, Silverman LM. A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N Engl J Med 1994;331:974-980.
24. Clancy JP. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med 2001;163:1683-1692.
25. LeGrys VA. Sweat testing for the diagnosis of cystic fibrosis: practical considerations. J Pediatr 1996;129:892-897.
26. Knowles MR, Paradiso AM, Boucher RC. In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum Gene Ther 1995;6:445-455.
27. Wilcken B, Wiley V, Sherry G, Bayliss U. Neonatal screening for cystic fibrosis: a comparison of two strategies for case detection in 1.2 million babies. J Pediatr 1995;127:965-970.
28. Rosenstein BJ, Cutting GR. Cystic Fibrosis Foundation Consensus Panel: the diagnosis of cystic fibrosis: a consensus statement. J Pediatr 1998; 132:589-595.
29. Rosenstein BJ. Cystic fibrosis diagnosis: new dilemmas for an old disorder. Pediatr Pulmonol 2002;33:83-84.
30. World Health Organization [WHO]. World Health Organization Classification of Cystic Fibrosis and Related Disorders. Stockholm: WHO; 2000. Report No. WHO/CF/HGN/00.2.
31. Chillon M, Casals T, Mercier B, Bassas L, Lissens W, Silber S, Romey MC, Ruiz-Romero J, Verlingue C, Claustres M. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med 1995;332:1475-1480.
32. Casals T, Bassas L, Egozcue S, Ramos MD, Gimenez J, Segura A, Garcia F, Carrera M, Larriba S, Sarquella J, et al. Heterogeneity for mutations in the CFTR gene and clinical correlations in patients with congenital absence of the vas deferens. Hum Reprod 2000;15;1476-1483.
33. Cohn JA, Friedman KJ, Noone PG, Knowles MR, Silverman LM, Jowell PS. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. N Engl J Med 1998;339:653-658.
34. Wang X, Moylan B, Leopold DA, Kim J, Rubenstein RC, Togias A, Proud D, Zeitlin PL, Cutting GR. Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinosinusitis in the general population. JAMA 2000;284:1814-1819.
35. Groman JD, Meyer M, Wilmott R, Zeitlin P, Cutting G. Variant cystic fibrosis phenotypes in the absence of CFTR mutations. N Engl J Med 2002;347:401-407.
36. Bush A, Wallis C. Time to think again: cystic fibrosis is not an "all or none" disease. Pediatr Pulmonol 2000;30:139-144.
37. Tomashefski JF Jr, Konstan MW, Bruce MC, Abramowsky CR. The pathologic characteristics of interstitial pneumonia cystic fibrosis: a retrospective autopsy study. Am J Clin Pathol 1989;91:522-530.
38. Engelhardt JF, Yankaskas JR, Ernst SA, Yang Y, Marino CR, Boucher RC, Cohn JA, Wilson JM. Submucosal glands are the predominant site of CFTR expression in the human bronchus. Nat Genet 1992;2:240-248.
39. Ornoy A, Arnon J, Katznelson D, Granat M, Caspi B, Chemke J. Pathological confirmation of cystic fibrosis in the fetus following prenatal diagnosis. Am J Med Genet 1987;28:935-947.
40. Chow CW, Landau LI, Taussig LM. Bronchial mucous glands in the newborn with cystic fibrosis. Eur J Pediatr 1982;139:240-243.
41. Strugess J, Imrie J. Quantitative evaluation of the development of tracheal submucosal glands in infants with cystic fibrosis and control infants. Am J Pathol 1982;106:303-311.
42. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995;151:1075-1082.
43. Muhlebach MS, Stewart PW, Leigh MW, Noah TL. Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med 1999;160:186-191.
44. Balough K, McCubbin M, Weinberger M, Smits W, Ahrens R, Fick R. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol 1995; 20:63-70.
45. Gutierrez JP, Grimwood K, Armstrong DS, Carlin JB, Carzino R, Olinsky A, Robertson CF, Phelan PD. Interlobar differences in bronchoalveolar lavage fluid from children with cystic fibrosis. Eur Respir J 2001; 17:281-286.
46. Tiddens HA. Detecting early structural lung damage in cystic fibrosis. Pediatr Pulmonol 2002;34:228-231.
47. Meyer KC, Sharma A. Regional variability of lung inflammation in cystic fibrosis. Am J Respir Crit Care Med 1997;156:1536-1540.
48. Armstrong DS, Grimwood K, Carlin JB, Carzino R, Gutierrez JP, Hull J, Olinsky A, Phelan EM, Robertson CF, Phelan PD. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 1997;156:1197-1204.
49. Dakin CJ, Numa AH, Wang H, Morton JR, Vertzyas CC, Henry RL. Inflammation, infection, and pulmonary function in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 2002;165:904-910.
50. Rosenfeld M, Gibson RL, McNamara S, Emerson J, Burns JL, Castile R, Hiatt P, McCoy K, Wilson CB, Inglis A, et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol 2001;32:356-366.
51. Konstan MW, Hilliard KA, Norvell TM, Berger M. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 1994;150:448-454.
52. Chmiel JF, Berger M, Konstan MW. The role of inflammation in the pathophysiology of CF lung disease. Clin Rev Allergy Immunol 2002; 23:5-27.
53. Bonfield TL, Panuska JR, Konstan MW, Hilliard KA, Hilliard JB, Ghnaim H, Berger M. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995;152:2111-2118.
54. Ogrinc GB, Kampalath B, Tomashefski JF Jr. Destruction and loss of bronchial cartilage in cystic fibrosis. Hum Pathol 1998;29:65-73.
55. Durieu I, Peyrol S, Gindre D, Bellon G, Durand DV, Pacheco Y. Subepithelial fibrosis and degradation of the bronchial extracellular matrix in cystic fibrosis. Am J Respir Crit Care Med 1998;158:580-588.
56. Konstan MW, Davis PB. Pharmacological approaches for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis. Adv Drug Deliv Rev 2002;54:1409-1423.
57. Tirouvanziam R, de Bentzmann S, Hubeau C, Hinnrasky J, Jacquot J, Peault B, Puchelle E. Inflammation and infection in naive human cystic fibrosis airway grafts. Am J Respir Cell Mol Biol 2000;23:121-127.
58. Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 1990;87:9188-9192.
59. Hiatt PW, Grace SC, Kozinetz CA, Raboudi SH, Treece DG, Taber LH, Piedra PA. Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics 1999;103:619-626.
60. Hyde SC, Emsley P, Hartshorn MJ, Mimmack MM, Gileadi U, Pearce SR, Gallagher MP, Gill DR, Hubbard R, Higgins C. Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature 1990;346:362-365.
61. Ostedgaard L, Baldursson O, Welsh MJ. Regulation of the cystic fibrosis transmembrane conductance regulator Cl- channel by its R domain. J Biol Chem 2001;276:7689-7692.
62. Anderson MP, Berger HA, Rich DP, Gregory RJ, Smith AE, Welsh MJ. Nucleoside triphosphates are required to open the CFTR chloride channel. Cell 1991;67:775-784.
63. Gadsby DC, Narin AC. Control of CFTR channel gating by phosphorylation and nucleotide hydrolysis. Physiol Rev 1999;79:S77-S107.
64. Boucher RC. An overview of the pathogenesis of cystic fibrosis lung disease. Adv Drug Deliv Rev 2002;54:1359-1371.
65. Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy J, Davis CW, Boucher RC. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998;95:1005-1015.
66. Knowles MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest 2002;109:571-577.
67. Smith JJ, Travis SM, Greenberg EP, Welsh MJ. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996;85:229-236.
68. Guggino WB. Cystic fibrosis and the salt controversy. Cell 1999;96:607-610.
69. Guggino WB. Cystic fibrosis salt/fluid controversy: in the thick of it. Nat Med 2001;7:888-889.
70. Wine JJ. The genesis of cystic fibrosis lung disease. J Clin Invest 1999;103:309-312.
71. Verkman AS, Song Y, Thiagarajah JR. Role of airway surface liquid and submucosal glands in cystic fibrosis lung disease. Am J Physiol Cell Physiol 2003;284:C2-C15.
72. Knowles MR, Robinson JM, Wood RE, Pue CA, Mentz WM, Wager GC, Gatzy JT, Boucher RC. Ion composition of airway surface liquid of patients with cystic fibrosis as compared with normal and disease-control subjects. J Clin Invest 1997;100:2588-2595.
73. Jayaraman S, Song Y, Vetrivel L, Shankar L, Verkman AS. Noninvasive in vivo fluorescence measurement of airway-surface liquid depth, salt concentration, and pH. J Clin Invest 2001;107:317-324.
74. Caldwell RA, Grubb BR, Tarran R, Boucher RC, Knowles M, Barker PM. In vivo airway surface liquid Cl- analysis with solid-state electrodes. J Gen Physiol 2002;119:3-14.
75. Jayaraman S, Song Y, Verkman AS. Airway surface liquid osmolality measured using fluorophore-encapsulated liposomes. J Gen Physiol 2001;117:423-430.
76. Widdicombe JH. Altered NaCl concentration of airway surface liquid in cystic fibrosis. Pflugers Arch 2001;443:S8-S10.
77. Jayaraman S, Joo NS, Reitz B, Wine JJ, Verkman AS. Submucosal gland secretions in airways from cystic fibrosis patients have normal [Na(+)] and pH but elevated viscosity. Proc Natl Acad Sci USA 2001;98:8119-8123.
78. Robinson M, Bye PT. Mucociliary clearance in cystic fibrosis. Pediatr Pulmonol 2002;33:293-306.
79. Joo NS, Irokawa T, Wu JV, Robbins RC, Whyte RI, Wine J. Absent secretion to vasoactive intestinal peptide in cystic fibrosis airway glands. J Biol Chem 2002;277:50710-50715.
80. Cole AM, Dewan P, Ganz T. Innate antimicrobial activity of nasal secretions. Infect Immun 1999;67:3267-3275.
81. Immundo L, Barasch J, Prince A, Al-Awquit Q. Cystic fibrosis epithelial cells have a receptor for pathogenic bacteria on their apical surface. Proc Natl Acad Sci USA 1995;92:3019-3023.
82. de Bentzmann S, Roger P, Dupuit F, Bajolet-Laudinat O, Fuchey C, Plotkowski MC, Puchelle E. Asialo GM1 is a receptor for Pseudomonas aeruginosa adherence to regenerating respiratory epithelial cells. Infect Immun 1996;64:1582-1588.
83. DiMango E, Ratner AJ, Bryan R, Tabibi S, Prince A. Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells. J Clin Invest 1998;101:2598-2605.
84. Zar H, Saiman L, Quittell L, Prince A. Binding of Pseudomonas aeruginosa to respiratory epithelial cells from patients with various mutations in the cystic fibrosis transmembrane regulator. J Pediatr 1995;126:230-233.
85. Bryan R, Kube D, Perez A, Davis P, Prince A. Overproduction of the CFTR R domain leads to increased levels of asialoGM1 and increased Pseudomonas aeruginosa binding by epithelial cells. Am J Respir Cell Mol Biol 1998;19:269-277.
86. Poschet JF, Boucher JC, Tatterson L, Skidmore J, Van Dyke RW, Deretic V. Molecular basis for defective glycosylation and Pseudomonas pathogenesis in cystic fibrosis lung. Proc Natl Acad Sci USA 2002;98:13927-13977.
87. Schroeder TH, Zaidi TS, Pier GB. Lack of adherence of clinical isolates of Pseudomonas aeruginosa to asialo-GM on epithelial cells. Infect Immun 2001;69:719-729.
88. Plotkowski MC, Costa AO, Morandi V, Barbosa HS, Nader HB, de Bentzmann S, Puchelle E. Role of heparan sulphate proteoglycans as potential receptors for non-piliated Pseudomonas aeruginosa adherence to non-polarised airway epithelial cells. J Med Microbiol 2001; 50:183-190.
89. Pier GB, Grout M, Zaidi TS. Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung. Proc Natl Acad Sci USA 1997;94:12088-12093.
90. Pier GB. Role of the cystic fibrosis transmembrane conductance regulator in innate immunity to Pseudomonas aeruginosa infections. Proc Natl Acad Sci USA 2000;97:8822-8828.
91. Pier GB. CFTR mutations and host susceptibility to Pseudomonas aeruginosa lung infection. Curr Opin Microbiol 2002;5:81-86.
92. Coleman FT, Mueschenborn S, Meluleni G, Ray C, Carey VJ, Vargas SO, Cannon CL, Ausubel FM, Pier GB. Hypersusceptibility of cystic fibrosis mice to chronic Pseudomonas aeruginosa oropharyngeal colonization and lung infection. Proc Natl Acad Sci USA 2003;100:1949-1954.
93. Schroeder TH, Lee MM, Yacono PW, Cannon CL, Gerceker AA, Golan DE, Pier GB. CFTR is a pattern recognition molecule that extracts Pseudomonas aeruginosa LPS from the outer membrane into epithelial cells and activates NF-kappa B translocation. Proc Natl Acad Sci USA 2002;99:6907-6912.
94. Schroeder TH, Reiniger N, Meluleni G, Grout M, Coleman FT, Pier GB. Transgenic cystic fibrosis mice exhibit reduced early clearance of Pseudomonas aeruginosa from the respiratory tract. J Immunol 2001;166:7410-7418.
95. Hajjar AM, Ernst RK, Tsai JH, Wilson CB, Miller SI. Human toll-like receptor 4 recognizes host-specific LPS modifications. Nat Immunol 2002;3:354-359.
96. Ernst RK, Yi EC, Guo L, Lim KB, Burns JL, Hackett M, Miller SI. Specific lipopolysaccharide found in cystic fibrosis airway Pseudomonas aeruginosa. Science 1999;286:1561-1565.
97. Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekicki A, Meyer KC, Birrer P, Bellon G, Jurgen B, Weiss T. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002;109:317-325.
98. Ulrich M, Herbert S, Berger J, Bellon G, Louis D, Munker G, Doring G. Localization of Staphylococcus aureus in infected airways of patients with cystic fibrosis and in a cell culture model of S. aureus adherence. Am J Respir Cell Mol Biol 1998;19:83-91.
99. Bals R, Weiner DE, Wilson JM. The innate immune system in cystic fibrosis lung disease. J Clin Invest 1999;103:303.
100. Ganz T. Antimicrobial polypeptides in host defense of the respiratory tract. J Clin Invest 2002;109:693-697.
101. Hancock RE, Lehrer RI. Cationic peptides: a new source of antibiotics. Trends Biotechnol 1998;16:82-88.
102. Garred P, Pressler T, Madsen HO, Frederiksen B, Svejgaard A, Hoiby N, Schwartz M, Koch C. Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest 1999;104:431-437.
103. Gabolde M, Guilloud-Bataille M, Feingold J, Besmond C. Association of variant alleles of mannose binding lectin with severity of pulmonary disease in cystic fibrosis: cohort study. BMJ 1999;319:1166-1167.
104. Thiel S, Vorup-Jensen T, Stover CM, Schwaeble W, Laursen SB, Poulsen K, Willis AC, Eggleton P, Hansen S, Holmskov U, et al. A second serine protease associated with mannan-binding lectin that activates complement. Nature 1997;386:506-510.
105. Davies J, Neth O, Alton E, Klein N, Turner M. Differential binding of mannose-buiding lectin to respiratory pathogens in cystic fibrosis. Lancet 2000;355:1885-1886.
106. Weiner DJ, Bucki R, Janmey PA. The antimicrobial activity of the cathelicidin LL37 is inhibited by F-actin bundles and restored by gelsolin. Am J Respir Cell Mol Biol 2003;28:738-745.
107. Burns JL, Gibson R, McNamara S, Yim D, Emerson J, Rosenfeld M, Hiatt P, McCoy K, Castile R, Smith A, et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 2001;183:444-452.
108. West SE, Zeng L, Lee B, Kosorok MR, Laxova A, Rock M, Splaingard M, Farrell P. Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis: early detection by serology and assessment of risk factors. JAMA 2002;287:2958-2967.
109. Doring G, Albus A, Hoiby N. Immunologic aspects of cystic fibrosis. Chest 1988;94:109S-115S.
110. Ciofu O, Petersen TD, Jensen P, Hoiby N. Avidity of anti-P aeruginosa antibodies during chronic infection in patients with cystic fibrosis. Thorax 1999;54:141-144.
111. Barnes PJ. Nuclear factor-B: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-1071.
112. Venkatakrishnan A, Stecenko A, King G, Blackwell TR, Brigham KL, Christman JW, Blackwell TS. Exaggerated activation of nuclear factor-kB and altered IkB-B process in cystic fibrosis bronchial epithelial cells. Am J Respir Cell Mol Biol 2000;23:396-403.
113. Aldallal N, McNaughton EE, Manzel LJ, Richards AM, Zabner J, Ferkol TW, Look DC. Inflammatory response in airway epithelial cells isolated from patients with cystic fibrosis. Am J Respir Crit Care Med 2002;166:1248-1256.
114. Weber A, Soong G, Bryan B, Saba S, Prince A. Activation of NF-kappaB in airway epithelial cells is dependent on CFTR trafficking and Cl- channel function. Am J Physiol Lung Cell Mol Physiol 2001;281:L71-L78.
115. Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. Clin Microbiol Rev 2002;15:194-222.
116. Thomassen MJ, Demko CA, Doershuk C. Cystic fibrosis: a review of pulmonary infections and interventions. Pediatr Pulmonol 1987;3:334-351.
117. Ratjen F, Comes G, Paul K, Posselt HG, Wagner TO, Harms K. German Board of the European Registry for Cystic Fibrosis (ERCF): effect of continuous antistaphylococcal therapy on the rate of P. aeruginosa acquisition in patients with cystic fibrosis. Pediatr Pulmonol 2001;31: 13-16.
118. Stutman HR, Lieberman JM, Nussbaum E, Marks MI. Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial. J Pediatr 2002;140:299-305.
119. Armstrong DS, Grimwood K, Carlin JB, Carzino R, Olinsky A, Phelan PD. Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis. Pediatr Pulmonol 1996;21:267-275.
120. Barker AF. Bronchiectasis. N Engl J Med 2002;346:1383-1393.
121. Maselli JH, Sontag MK, Norris JM, MacKenzie T, Wagener JS, Accurso FJ. Risk factors for initial acquisition of Pseudomonas aeruginosa in children with cystic fibrosis identified by newborn screening. Pediatr Pulmonol 2003;35:257-262.
122. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002;34:91-100.
123. Nixon GM, Armstrong DS, Carzino R, Carlin JB, Olinsky A, Robertson CF, Grimwood K. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001;138:699-704.
124. Demko CA, Byard PJ, Davis PB. Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. J Clin Epidemiol 1995;48:1041-1049.
125. Armstrong DS, Nixon GM, Carzino R, Bigham A, Carlin JB, Robins-Browne RM, Grimwood K. Detection of a widespread clone of Pseudomonas aeruginosa in a pediatric cystic fibrosis clinic. Am J Respir Crit Care Med 2002;166:983-987.
126. Speert DP, Campbell ME, Henry DA, Milner R, Taha F, Gravelle A, Davidson AG, Wong LT, Mahenthiralingam E. Epidemiology of Pseudomonas aeruginosa in cystic fibrosis in British Columbia, Canada. Am J Respir Crit Care Med 2002;166:988-993.
127. Jung A, Kleinau I, Schonian G, Bauernfeind A, Chen C, Griese M, Doring G, Gobel U, Wahn U, Paul K. Sequential genotyping of Pseudomonas aeruginosa from upper and lower airways of cystic fibrosis patients. Eur Respir J 2002;20:1457-1463.
128. Hancock RE, Mutharia LM, Chan L, Darveau RP, Speert DP, Pier GB. Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains. Infect Immun 1983;42:170-177.
129. Luzar MA, Montie TC. Avirulence and altered physiological properties of cystic fibrosis strains of Pseudomonas aeruginosa. Infect Immun 1985;50:572-576.
130. Thomas SR, Ray A, Hodson M, Pitt T. Increased sputum amino acid concentrations and auxotrophy of Pseudomonas aeruginosa in severe cystic fibrosis lung disease. Thorax 2000;55:795-797.
131. Lam J, Chan R, Lam K, Costerton JW. Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis. Infect Immun 1980;28:546-556.
132. Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 2000;407:762-764.
133. Drenkard E, Ausubel FM. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 2002;416:740-743.
134. Nickel JC, Wright JB, Ruseska I, Marrie TJ, Whitfield C, Costerton JW. Antibiotic resistance of Pseudomonas aeruginosa colonizing a urinary catheter in vitro. Eur J Clin Microbiol 1985;4:213-218.
135. Spoering AL, Lewis K. Biofilms and planktonic cells of Pseudomonas aeruginosa have similar resistance to killing by antimicrobials. J Bacteriol 2001;183:6746-6751.
136. Prince A. Biofilms, antimicrobial resistance, and airway infection. N Engl J Med 2002;347:1110-1111.
137. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999;284:1318-1322.
138. Hentzer M, Teitzel GM, Balzer GT, Heydorn A, Molin S, Givskov M, Parsek MR. Alginate overproduction affects Pseudomonas aeruginosa biofilm structure and function. J Bacteriol 2001;183:5395-5401.
139. Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrener P, Hickey MJ, Brinkman FS, Hufnagle WO, Kowalik DJ, Lagrou M, et al. Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature 2000;406:959-964.
140. Spencer D, Kas A, Smith E, Raymond CK, Sims EH, Hastings M, Bums J, Kaul R, Olson MV. Whole-genome sequence variation among multiple isolates of Pseudomonas aeruginosa. J Bacteriol 2003;185: 1316-1325.
141. Oliver A, Canton R, Campo P, Baquero F, Blazquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000;88:1251-1254.
142. Thomassen MJ, Demko CA, Klinger JD, Stern RC. Pseudomonas cepacia colonization among patients with cystic fibrosis: a new opportunist. Am Rev Respir Dis 1985;131:791-796.
143. Isles A, Maclusky I, Corey M, Gold R, Prober C, Fleming P, Levison H. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr 1984;104:206-210.
144. Vandamme P, Henry DA, Coenye T, Nzula S, Vancanneyt M, LiPuma JJ, Speert DP, Govan JR, Mahenthiralingam E. Burkholderia anthina sp. nov. and Burkholderia pyrrocinica, two additional Burkholderia cepacia complex bacteria, may confound results or new molecular diagnostic tools. FEMS Immunol Med Microbiol 2002;33:143-149.
145. Coenye T, Vandamme P, Govan JR, LiPuma JJ. Taxonomy and identification of the Burkholderia cepacia complex. J Clin Microbiol 2001;39: 3427-3436.
146. LiPuma JJ, Spilker T, Gill LH, Campbell PW III, Liu L, Mahenthiralingam E. Disproportionate distribution of Burkholderia cepacia complex species and transmissibility markers in cystic fibrosis. Am J Respir Crit Care Med 2001;164:92-96.
147. Mahenthiralingam E, Vandamme P, Campbell ME, Henry DA, Gravelle AM, Wong LT, Davidson AG, Wilcox PG, Nakielna B, Speert DP. Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clin Infect Dis 2001;33:1469-1475.
148. Sun L, Jiang RZ, Steinbach S, Holmes A, Campanelli C, Forstner J, Sajjan U, Tan YK, Riley M, Goldstein R. The emergence of a highly transmissible lineage of cbl+ Pseudomonas (Burkholderia) cepacia causing CF centre epidemics in North America and Britain. Nat Med 1995;1:661-666.
149. Goss CH, Otto KL, Aitken ML, Rubenfeld GD. Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis. Am J Respir Crit Care Med 2002;166:356-361.
150. Tan KK, Conway SP, Brownlee KG, Etherington C, Peckham G. Alcaligenes infection in cystic fibrosis. Pediatr Pulmonol 2002;34:101-104.
151. Krzewinski JW, Nguyen CD, Foster JM, Burns JL. Use of random amplified polymorphic DNA PCR to examine epidemiology of Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans from patients with cystic fibrosis. J Clin Microbiol 2001;39:3597-3602.
152. Bargon J, Dauletbaev N, Kohler B, Wolf M, Posselt HG, Wagner TO. Prophylactic antibiotic therapy is associated with an increased prevalence of Aspergillus colonization in adult cystic fibrosis patients. Respir Med 1999;93:835-838.
153. Burns JL, Emerson J, Stapp JR, Yim DL, Krzewinski J, Louden L, Ramsey BW, Clausen CR. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 1998;27:158-163.
154. Bakare N, Rickerts V, Bargon J, Just-Nubbling G. Prevalence of Aspergillus fumigatus and other fungal species in the sputum of adult patients with cystic fibrosis. Mycoses 2003;46:19-23.
155. Stevens DA, Moss RB, Kurup VP, Knutsen AP, Greenberger P, Judson MA, Denning DW, Crameri R, Brody AS, Light M, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003;37(Suppl 3):S225-S264.
156. Greenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 2002;110:685-692.
157. Moss R. Allergic bronchopulmonary aspergillosis. Clin Rev Allergy Immunol 2002;23:87-104.
158. Taccetti G, Procopio E, Marianelli L, Campana S. Allergic bronchopulmonary aspergillosis in Italian cystic fibrosis patients: prevalence and percentage of positive tests in the employed diagnostic criteria. Eur J Epidemiol 2000;16:837-S42.
159. Mastella G, Rainisio M, Harms HK, Hodson M, Koch C, Navarro J, Strandvik B, McKenzie SG. Epidemiologic Registry of Cystic Fibrosis: allergic bronchopulmonary aspergillosis in cystic fibrosis: a European epidemiologic study. Eur Respir J 2001;16:464-471.
160. Cimon B, Carrere J, Vinatier JF, Chazalette JP, Chabasse D, Bouchara JP. Clinical significance of Scedosporium apiospermum in patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2000;19:53-56.
161. Cimon B, Symoens F, Zouhair R, Chabasse D, Nolard N, Defontaine A, Bouchara JP. Molecular epidemiology of airway colonisation by Aspergillus fumigatus in cystic fibrosis patients. J Med Microbiol 2001;50:367-374.
162. Defontaine A, Zouhair R, Cimon B, Carrere J, Bailly E, Symoens F, Diouri M, Hallet JN, Bouchara JP. Genotyping study of Scedosporium apiospermum isolates from patients with cystic fibrosis. J Clin Microbiol 2002;40:2108-2114.
163. Cimon B, Carrere J, Chazalette JP, Vinatier JF, Chabasse D, Bouchara JP. Chronic airway colonization by Penicillium emersonii in a patient with cystic fibrosis. Med Mycol 1999;37:291-293.
164. Diemert D, Kunimoto D, Sand C, Rennie R. Sputum isolation of Wangiella dermatitidis in patients with cystic fibrosis. Scand J Infect Dis 2001;33:777-779.
165. Olivier KN, Weber DJ, Wallace RJ Jr, Faiz AR, Lee JH, Zhang Y, Brown-Elliot BA, Handler A, Wilson RW, Schechter MS, et al. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003;167:828-834.
166. Olivier KN, Weber DJ, Lee JH, Handler A, Tudor G, Molina PL, Tomashefski J, Knowles MR. Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med 2003;167:835-840.
167. Clinical Practice Guidelines for Cystic Fibrosis. Bethesda, MD: Cystic Fibrosis Foundation; 1997.
168. Sood N, Paradowski LJ, Yankaskas JR. Outcomes of intensive care unit care in adults with cystic fibrosis. Am J Respir Crit Care Med 2001; 163:335-338.
169. Wallick K, Nick JA, Rodman DM. Cystic fibrosis critical care: no longer an oxymoron. Am J Respir Crit Care Med 2001;163:310-312.
170. Yankaskas JR, Mallory GB Jr. Lung transplantation in cystic fibrosis: consensus conference statement Chest 1998;113:217-226.
171. Schidlow DV, Taussig LM, Knowles MR. Cystic Fibrosis Foundation consensus conference report on pulmonary complications of cystic fibrosis. Pediatr Pulmonol 1993;15:187-198.
172. Piper AJ, Parker S, Torzillo PJ, Sullivan CE, Bye PT. Nocturnal nasal IPPV stabilizes patients with cystic fibrosis and hypercapnic respiratory failure. Chest 1992;102:846-850.
173. Orenstein DM. Terminal care. In: Orenstein DM, Stern RC, editors. Treatment of the hospitalized cystic fibrosis patient. New York: Marcel Dekker; 1998. p. 357-376.
174. Brasfield D, Hicks G, Soong S, Tiller RE. The chest roentgenogram in cystic fibrosis: a new scoring system. Pediatrics 1979;63:24-29.
175. Shwachman H, Kowalski SM, Shaw KT. Cystic fibrosis: a new outlook: 70 patients above 25 years of age. Medicine (Baltimore) 1977;56:129-149.
176. Weatherly MR, Palmer CG, Peters ME, Green CG, Fryback D, Langhough R, Farrell PM. Wisconsin cystic fibrosis chest radiograph scoring system. Pediatrics 1993;91:488-495.
177. Brody AS. Cystic fibrosis: when should high-resolution computed tomography of the chest be obtained? Pediatrics 1998;101:1071.
178. Shah RM, Sexauer W, Ostrum BJ, Fiel SB, Friedman AC. High-resolution CT in the acute exacerbation of cystic fibrosis: evaluation of acute findings, reversibility of those findings, and clinical correlation. Am J Roentgenol 1997;169:375-380.
179. Bhalla M, Turcios N, Aponte V, Jenkins M, Leitman BS, McCauley DI, Naidich DP. Cystic fibrosis: scoring system with thin-section CT. Radiology 1991;179:783-788.
180. Helbich TH, Heinz-Peer G, Fleischmann D, Wojnarowski C, Wunderbaldinger P, Huber S, Eichler I, Herold CJ. Evolution of CT findings in patients with cystic fibrosis. AJR Am J Roentgenol 1999;173:81-88.
181. Maffessanti M, Candusso M, Brizzi F, Piovesana F. Cystic fibrosis in children: HRCT findings and distribution of disease. J Thorac Imaging 1996;11:27-38.
182. Santamaria F, Grille G, Guidi G, Rotondo A, Raia V, de Ritis G, Sarnelli P, Caterino M, Greco L. Cystic fibrosis: when should high-resolution computed tomography of the chest be obtained? Pediatrics 1998;101:908-913.
183. Crapo RO. Pulmonary-function testing. N Engl J Med 1994;331:25-30.
184. Cooper C, Robertson C, Hudson I, Phelan P. Variability of pulmonary function tests in cystic fibrosis. Pediatr Pulmonol 1990;8:16-22.
185. Nickerson BG, Lemen RJ, Gerdes CB, Wegmann MJ, Robertson G. Within-subject variability and percent change for significance of spirometry in normal subjects and in patients with cystic fibrosis. Am Rev Respir Dis 1980;122:859-866.
186. Davis PB, Byard PJ, Konstan MW. Identifying treatments that halt progression of pulmonary disease in cystic fibrosis. Pediatr Res 1997; 41:161-165.
187. Ramsey BW, Boat TF. Outcome measures for clinical trials in cystic fibrosis: summary of a Cystic Fibrosis Foundation Consensus Conference. J Pediatr 1994;124:177-192.
188. Corey M, Edwards L, Levison H, Knowles M. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr 1997;131:809-814.
189. Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983;127:725-734.
190. Dockery DW, Berkey CS, Ware JH, Speizer FE, Ferris BG Jr. Distribution of forced vital capacity and forced expiratory volume in one second in children 6 to 11 years of age. Am Rev Respir Dis 1983;128: 405-412.
191. Wang X, Dockery DW, Wypig D, Fay ME, Ferris BG Jr. Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol 1993;15: 75-88.
192. Kerem E, Reisman J, Corey M, Canny GJ, Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992;326:1187-1191.
193. Corey M, Levison H, Crozier D. Five- to seven-year course of pulmonary function in cystic fibrosis. Am Rev Respir Dis 1976;114:1085-1092.
194. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001:153:345-352.
195. Hamblett N, Rosenfeld M, Emerson J, Goss CH, Aitken ML. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med 2002;166:1550-1555.
196. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME. The Pulmozyme Study Group: effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994;331:637-642.
197. Ramsey B, Pepe M, Quan JM, Otto KL, Montgomery AB, Williams-Warren J. Efficacy and safety of chronic intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340:23-30.
198. Steinkamp G, Wiedemann B. Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project. Thorax 2002;57:596-601.
199. Lanng S, Thorsteinsson B, Nerup J, Koch C. Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections. Acta Paediatr 1994;83:849-853.
200. Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med 2000;162:891-895.
201. Schaedel C, de Monestrol I, Hjelte L, Johannesson M, Kornfalt R, Lindblad A, Strandvik B, Wahlgren L, Holmberg L. Predictors of deterioration of lung function in cystic fibrosis. Pediatr Pulmonol 2002;33:483-491:
202. Gappa M, Ranganathan SC, Stocks J. Lung function testing in infants with cystic fibrosis: lessons from the past and future directions. Pediatr Pulmonol 2001;32228-245.
203. Turner DJ, Stick SM, Lesouef KL, Sly PD, Lesouef PN. A new technique to generate and assess forced expiration from raised lung volume in infants. Am J Respir Crit Care Med 1995;151:1441-1450.
204. Turner DJ, Lanteri CJ, Lesouef PN, Sly PD. Improved detection of abnormal respiratory function using forced expiration from raised lung volume in infants with cystic fibrosis. Eur Respir J 1994;7:1995-1999.
205. Feher A, Castile R, Kisling J, Angelicchio C, Filbrum D, Flucke R, Tepper RS. Flow limitation in normal infants: a new method for forced expiratory maneuvers from raised lung volumes. J Appl Physiol 1996; 80:2019-2025.
206. Jones M, Castile R, Davis S, Kisling J, Filburn D, Flucke R, Goldstein A, Emsley C, Ambrosius W, Tepper RS. Forced expiratory flows and volume in infants: normative data and lung growth. Am J Respir Crit Care Med 2000;161:353-359.
207. Castile R, Filbrun D, Flucke R, Franklin W, McCoy K. Adult-type pulmonary function tests in infants without respiratory disease. Pediatr Pulmonol 2000;30:215-227.
208. Ranganathan SC, Bush A, Dezateux C, Carr S, Hoo A, Madge S, Prince J, Stroobant J, Wade A, Wallis C, et al. Relative ability of full and partial forced expiratory maneuvers to identify diminished airway function in infants with cystic fibrosis. Am J Respir Crit Care Med 2002;166:1350-1357.
209. Ranganathan SC, Dezateux C, Bush A, Carr S, Castle RA, Madge S, Price J, Stroobant J, Wade A, Wallis C, et al. Airway function in infants newly diagnosed with cystic fibrosis. Lancet 2001;358:1964-1965.
210. Modi M, Eber E, Weinhandl E, Gruber WC, Zach MS. Reproductibility of forced expiratory flow and volume measurements in infants with bronchiolitis. Pediatr Pulmonol 1999;28:429-435.
211. Eigen H, Bieler H, Grant D, Christoph K, Terrill D, Heilman D, Ambrosius W, Tepper RS. Spirometic pulmonary function in healthy preschool children. Am J Respir Crit Care Med 2001;163:619-623.
212. Marostica PJ, Weist AD, Eigen H, Angelicchio C, Christoph K, Savage J, Grant D, Tepper RS. Spirometry in 3- to 6-year-old children with cystic fibrosis. Am J Respir Crit Care Med 2002;166:67-71.
213. Nielsen KG, Bisgaard H. Discriminative capacity of bronchodilator response measured with three different lung function techniques in asthmatic and healthy children aged 2 to 5 years. Am J Respir Crit Care Med 2001;164:554-559.
214. Lebecque P, Stanescu D. Respiratory resistance by the forced oscillation technique in asthmatic children and cystic fibrosis patients. Eur Respir J 1997;10:891-895.
215. Beydon N, Amsallem F, Bellet M, Boule M, Chaussain M, Denjean A, Matran R, Pin I, Alberti C, Gaultier C. Respiratory resistance by the forced oscillation technique in asthmatic children and cystic fibrosis patients. Am J Respir Crit Care Med 2002;166:1099-1104.
216. Merkus PJ, Arets HG, Joosten T, Siero A, Brouha M, Mijnsbergen JY, de Jongste JC, van der Ent CK. Measurements of interrupter resistance: reference values for children 3-13 years of age. Eur Respir J 2002;20:907-911.
217. Kiska DL, Kerr A, Jones MC, Caracciolo JA, Eskridge B, Jordan M, Miller S, Hughes D, King N, Gilligan PH. Accuracy of four commercial systems for identification of Burkholderia cepacia and other Gramnegative nonfermenting bacilli recovered from patients with cystic fibrosis. J Clin Microbiol 1996;34:886-891.
218. Shelly DB, Spilker T, Gracely EJ, Coenye T, Vandamme P. LiPuma JJ. Utility of commercial systems for identification of Burkholderia cepacia complex from cystic fibrosis sputum culture. J Clin Microbiol 2000;38:3112-3115.
219. Saiman L, Burns J, Larone D, Chen Y, Garber E, Whittier S. Evaluation of MicroScan Autoscan for identification of Pseudomonas aeruginosa isolates from cystic fibrosis patients. J Clin Microbiol 2003;41:492-494.
220. Burns JL, Saiman L, Whittier S, Krzewinski J, Liu Z, Larone D, Marshall SA, Jones RN. Comparison of two commercial systems (Vitek and MicroScan-WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. Diagn Microbiol Infect Dis 2001;39:257-260.
221. Thomassen MJ, Klinger JD, Badger SJ, van Heeckeren DW, Stern RC. Cultures of thoracotomy specimens confirm usefulness of sputum cultures in cystic fibrosis. J Pediatr 1984;104:352-356.
222. Henig NR, Tonelli MR, Pier MV, Bums JL, Aitken ML. Sputum induction as a research tool for sampling the airways of subjects with cystic fibrosis. Thorax 2001;56:306-311.
223. Rosenfeld M, Emerson J, Accurso F, Armstrong D, Castile R, Grimwood K, Hiatt P, McCoy K, McNamara S, Ramsey B, et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol 1999;28:321-328.
224. Ramsey BW, Wentz KR, Smith A, Richardson M, Williams-Warren J, Hedges DL. Predictive value of oropharyngeal cultures for identifying lower airway bacteria in cystic fibrosis patients. Am Rev Respir Dis 1991;144:331-337.
225. Suri R, Marshall LJ, Wallis C, Metcalfe C, Shute JK, Bush A. Safety and use of sputum induction in children with cystic fibrosis. Pediatr Pulmonol 2003;35:309-313.
226. Sagel SD, Sontag MK, Wagener J, Kapsner R, Osberg I, Accurso F. Induced sputum inflammatory measures correlate with lung function in children with lung function. J Pediatr 2002;141:811-817.
227. Sagel SD, Kapsner R, Osberg I, Sontag MK, Accurso FJ. Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction. Am J Respir Crit Care Med 2001;164:1425-1431.
228. Carson LA, Tablan OC, Cusick LB, Jarvis WR, Favero MS, Bland LA. Comparative evaluation of selective media for isolation of Pseudomonas cepacia from cystic fibrosis patients and environmental sources. J Clin Microbiol 1988;26:2096-2100.
229. Henry DA, Campbell M, McGimpsey C, Clarke AR, Louden L, Burns J, Roe MH, Accurso F, Speert DP. Comparison of isolation media for recovery of Burkholderia cepacia complex from respiratory secretions of patients with cystic fibrosis. J Clin Microbiol 1999;37:1004-1007.
230. Wong K, Roberts MC, Owens L, Fife M, Smith AL. Selective media for the quantitation of bacteria in cystic fibrosis sputum. J Med Microbiol 1984;17:113-119.
231. Whitby PW, Carter KB, Burns J, Royall JA, LiPuma JJ, Stull TL. Identification and detection of Stenotrophomonas maltophilia by rRNA-directed PCR. J Clin Microbiol 2000;38:4305-4309.
232. Liu L, Coenye T, Burns J, Whitby PW, Stull TL, LiPuma JJ. Ribosomal DNA-directed PCR for identification of Achromobacter (Alcaligenes) xylosoxidans recovered from sputum samples from cystic fibrosis patients. J Clin Microbiol 2002;40:1210-1213.
233. Coenye T, Vandamme P, LiPuma JJ. Infection by Ralstonia species in cystic fibrosis patients: identification of R. pickettii and R. mannitolilytica by polymerase chain reaction. Emerg Infect Dis 2002;8:692-696.
234. Burns JL, Saiman L, Whittier S, Larone D, Krzewinski J, Liu Z, Marshall SA, Jones RN. Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. J Clin Microbiol 2000;38:1818-1822.
235. Chang S, Sievert DM, Hageman JC, Boulton ML, Tenover FC, Downes FP, Shah S, Rudrik JT, Pupp GR, Brown WJ, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003;348:1342-1347.
236. Staphylococcus aureus resistant to vancomycin: United States, 2002. MMWR Morb Mortal Wkly Rep 2002;51:565-567.
237. Staphylococcus aureus with reduced susceptibility to vancomycin: Illinois, 1999. MMWR Morb Mortal Wkly Rep 2000;48:1165-1167.
238. Lang BJ, Aaron SD, Ferris W, Hebert PC, MacDonald NE. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa. Am J Respir Crit Care Med 2000;162:2241-2245.
239. Aaron SD, Ferris W, Ramotar K, Vandemheen K, Chan F, Saginur R. Single and combination antibiotic susceptibilities of planktonic, adherent, and biofilm-grown Pseudomonas aeruginosa isolates cultured from sputa of adults with cystic fibrosis. J Clin Microbiol 2002; 40:4172-4179.
240. Jensen P, Johansen HK, Lanng S, Hoiby N. Relative increase in IgG antibodies to Pseudomonas aeruginosa 60-kD A GroEL in prediabetic patients with cystic fibrosis. Pediatr Res 2001;49:423-428.
241. Doring G, Hoiby N. Longitudinal study of immune response to Pseudomonas aeruginosa antigens in cystic fibrosis. Infect Immun 1983;42: 197-201.
242. Pressler T. IgG subclasses and chronic bacterial infection: subclass antibodies and the clinical course of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis. APMIS Suppl 1996;66:1-41.
243. Albus A, Saalmann M, Tesch H, Pedersen S, Doring G. Increased levels of IgG subclasses specific for Pseudomonas aeruginosa exoenzyme and polysaccharide antigens in chronically infected patients with cystic fibrosis. APMIS 1989;97:1146-1148.
244. Giordano A, Magni A, Filadoro F, Graziani C, Quattrucci S, Cipriani P. Study of IgG antibodies to Pseudomonas aeruginosa in early cystic fibrosis infection. New Microbiol 1998;21:375-378.
245. Likavcanova E, Lagace J. Quantitative analysis of immunoglobulin G subclass responses to Pseudomonas aeruginosa antigens in cystic fibrosis. J Med Microbiol 1992;36:437-444.
246. Gibson R, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003;167:841-849.
247. Hollsing AE, Granstrom M, Vasil ML, Wretlind B, Strandvik B. Prospective study of serum antibodies to Pseudomonas aeruginosa exoproteins in cystic fibrosis. J Clin Microbiol 1987;25:1868-1874.
248. Ratjen F, Doring G, Nikolaizik WH. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 2001;358:983-984.
249. Whittier S, Hopfer RL, Knowles M, Gilligan P. Improved recovery of mycobacteria from respiratory secretions of patients with cystic fibrosis. J Clin Microbiol 1993;31:861-864.
250. Doring G, Conway SP, Heijerman HG, Hodson M, Hoiby N, Smyth AR, Touw DJ. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000;16:749-767.
251. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997;23:330-335.
252. Wiesemann HG, Steinkamp G, Ratjen F, Bauernfeind A, Przyklenk B, Doring G, von der Hardt H. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 1998;25:88-92.
253. Munck A, Bonacorsi S, Mariani-Kurkdjian P, Lebourgeois M, Gerardin M, Brahimi N, Navarro J, Bingen E. Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization. Pediatr Pulmonol 2001;32:288-292.
254. FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr 1993;122:1-9.
255. Beardsmore CS, Thompson JR, Williams A, McArdle EK, Gregory GA, Weaver LT, Simpson H. Pulmonary function in infants with cystic fibrosis: the effect of antibiotic treatment. Arch Dis Child 1994;71:133-137.
256. Weaver LT, Green MR, Nicholson K, Mills J, Heeley ME, Kuzemko JA, Austin S, Gregory GA, Dux AE, Davis JA. Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period. Arch Dis Child 1994;70:84-89.
257. Parekh N, Subbarao P, Sweezey N. Association between prophylactic antibiotic usage and early onset of Pseudomonas aeruginosa. Pediatr Pulmonol 1998;26:324-345.
258. LowyFD. Staphylococcus aureus infections. N Engl J Med 1998;339:520-532.
259. Panlilio AL, Culver DH, Gaynes RP, Banerjee S, Henderson TS, Tolson JS, Martone WJ. Methicillin-resistant Staphylococcus aureus in US hospitals, 1975-1991. Infect Control Hosp Epidemiol 1992;13:582-586.
260. Smith T, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B, Tenover FC, Zervos MJ. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999;340:493-501.
261. Ferrin M, Zuckerman JB, Meagher A, Blumberg EA. Successful treatment of methicillin-resistant Staphylococcus aureus pulmonary infection with linezolid in a patient with cystic fibrosis. Pediatr Pulmonol 2002;33:221-223.
262. Sadowska B, Bonar A, von Eiff C, Proctor RA, Chmiela M, Rudnicka W, Rozalska B. Characteristics of Staphylococcus aureus, isolated from airways of cystic fibrosis patients, and their small colony variants. FEMS Immunol Med Microbiol 2002;32:191-197.
263. Kahl B, Hermann M, Everding AS, Koch HG, Becker K, Harms E, Proctor RA, Peters G. Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis. J Infect Dis 1998;177:1023-1029.
264. Haussler S, Tudie;mmler B, Rohde M, Steinmetz I. Small-colony variants of Pseudomonas aeruginosa in cystic fibrosis. Clin Infect Dis 1999;29: 621-625.
265. Looney WJ. Small-colony variants of Staphylococcus aureus. Br J Biomed Sd 2000;57:317-322.
266. Szaff M, Hoiby N, Flensborg EW. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand 1983;72:651-657.
267. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002;360:978-984.
268. MacLusky I, Levison H, Gold R, McLaughlin FJ. Inhaled antibiotics in cystic fibrosis: is there a therapeutic effect? J Pediatr 1986;108:861-865.
269. Mendelman PM, Smith AL, Levy J, Weber A, Ramsey B, Davis RL. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis 1985;132:761-765.
270. Levy J. Antibiotic activity in sputum. J Pediatr 1986;108:841-846.
271. Steinkamp G, Tümmler B, Gappa M, Albus A, Potel J, Doring G, von der Hardt H. Long-term tobramycin aerosol therapy in cystic fibrosis. Pediatr Pulmonol 1989;6:91-98.
272. Ramsey BW, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Kravitz RM, Schidlow DV, Wümott RW, Asüey SJ, McBurnie MA. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993;328:1740-1746.
273. Jensen T, Pedersen SS, Garne S, Heilmann C, Hoiby N, Koch C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987;19:831-838.
274. Littlewood JM, Miller MG, Ghoneim AT, Ramsden CH. Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis. Lancet 1985;1:865.
275. Valerius NH, Koch C, Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991;338:725-726.
276. Hodson ME, Gallagher CG, Govan JR. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 2002;20:658-664.
277. Dodd M, Abbott J, Maddison J, Moorcroft AJ, Webb AK. Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis. Thorax 1997;52:656-658.
278. Cunningham S, Prasad A, Collyer L, Carr S, Lynn IB, Wallis C. Bronchoconstriction following nebulised colistin in cystic fibrosis. Arch Dis Child 2001;84:432-433.
279. Fernández JD, Santiago RT, Matacon MP, Mayo RC, Sánchez GT. Inhaled aztreonam therapy in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. An Esp Pediatr 1994;40:185-188.
280. Bosso JA, Black PG. Controlled trial of aztreonam vs. tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis. Pediatr Infect Dis J 1988;7:171-176.
281. Bosso JA, Black PG, Matsen JM. Efficacy of aztreonam in pulmonary exacerbations of cystic fibrosis. Pediatr Infect Dis J 1987;6:393-397.
282. Prober CG, Walson PD, Jones J. Committee on Infectious Diseases and Committee on Drugs: technical report: precautions regarding the use of aerosolized antibiotics. Pediatrics 2000;106:E89.
283. Burns JL, Van Dalfsen JM, Shawar RM, Otto KL, Garber RL, Quan JM, Montgomery AB, Albers GM, Ramsey BW, Smith AL. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999; 179:1190-1196.
284. MacLeod DL, Nelson LE, Shawar RM, Lin BB, Lockwood LG, Dirk JE, Miller GH, Burns JL, Garber RL. Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment. J Infect Dis 2000;181:1180-1184.
285. Klinger JD, Aronoff SC. In-vitro activity of ciprofloxacin and other antibacterial agents against Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients. J Antimicrob Chemother 1985; 15:679-684.
286. Haller I. Comprehensive evaluation of ciprofloxacm-ammoglycoside combinations against Enterobacteriaceae and Pseudomonas aeruginosa strains. Antimicrob Agents Chemother 1985;28:663-666.
287. Reed MD, Stern RC, Myers CM, Yamashita TS, Blumer JL. Lack of unique ciprofloxacin pharmacokinetic characteristics in patients with cystic fibrosis. J Clin Pharmacol 1988;28:691-699.
288. Jensen T, Pedersen SS, Hoiby N, Koch C. Efficacy of oral fluroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis. Eur J Clin Microbiol 1987;6:618-622.
289. Bosso JA. Use of ciprofloxacin in cystic fibrosis patients. Am J Med 1989;87:123S-127S.
290. Hodson ME, Roberts CM, Butland RJ, Smith MJ, Batten JC. Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis. Lancet 1987;1:235-237.
291. Ball P. Emergent resistance to ciprofloxacin amongst Pseudomonas aeruginosa and Staphylococcus aureus: clinical significance and therapeutic approaches. J Antimicrob Chemother 1990;26(Suppl F):165-179.
292. Norrby SR. Side-effects of quinolones: comparisons between quinolones and other antibiotics. Eur J Clin Microbiol Infect Dis 1991;10:378-383.
293. Burkhardt JE, Hill MA, Carlton WW, Kesterson JW. Histologic and histochemical changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone. Vet Pathol 1990;27:162-170.
294. Hampel B, Hullmann R, Schmidt H. Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use: safety report. Pediatr Infect Dis J 1997;16:127-129.
295. Jick S. Ciprofloxacin safety in a pediatric population. Pediatr Infect Dis J 1997;16:130-134.
296. Chysky V, Kapila K, Hullmann R, Arcieri G, Schacht P, Echols R. Safety of ciprofloxacin in children: worldwide clinical experience based on compassionate use: emphasis on joint evaluation. Infection 1991; 19:289-296.
297. Piddock L, Johnson M, Ricci V, Hill L. Activitites of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract. Antimicrob Agents Chemother 1998;42:2956-2960.
298. Koyama H, Geddes DM. Erythromycin and diffuse panbronchiolitis. Thorax 1997;8:244.
299. Fujii T, Kadota J, Kawakami K, Iida K, Shirai R, Kaseda M, Kawamoto S, Kohno S. Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection. Thorax 1995;50:1246-1252.
300. Jaffe A, Francis J, Rosenthal M, Bush A. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet 1998; 351:420.
301. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002;57:212-216.
302. Hoiby N. Antibiotic therapy for chronic infection of pseudomonas in the lung. Annu Rev Med 1993;44:1-10.
303. Jaffe A, Bush A. Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol 2001;31:464-473.
304. Tateda K, Ishii Y, Matsumoto T, Furuya N, Nagashima M, Matsunaga T, Ohno A, Miyazaki S, Yamaguchi K. Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. Antimicrob Agents Chemother 1996;40:2271-2275.
305. Labro MT. Anti-inflammatory activity of macrolides: a new therapeutic potential? J Antimicrob Chemother 1998;41:37-46.
306. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell P. The Macrolide Study Group: a multicenter, randomized, placebo controlled, double-blind trial of azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. JAMA (In press)
307. Wood RE, Leigh MW. What is a "pulmonary exacerbation" in cystic fibrosis? J Pediatr 1987;111:841-842.
308. Dakin C, Henry RL, Field P, Morton J. Defining an exacerbation of pulmonary disease in cystic fibrosis. Pediatr Pulmonol 2001;31:436-442.
309. Rosenfeld M, Emerson J, Williams-Warren J, Pepe M, Smith A, Montgomery AB, Ramsey B. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001;139:359-365.
310. Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 1996;335:179-188.
311. Wolter JM, Bowler SD, Nolan PJ, McCormack JG. Home intravenous therapy in cystic fibrosis: a prospective randomized trial examining clinical, quality of life and cost aspects. Eur Respir J 1997;10:896-900.
312. Smith AL. Antibiotic therapy in cystic fibrosis: evaluation of clinical trials. J Pediatr 1986;108:866-870.
313. Michel BC. Antibacterial therapy in cystic fibrosis: a review of the literature published between 1980 and February 1987. Chest 1988;94: 129S-140S.
314. Regelmann WE, Elliott GR, Warwick WJ, Clawson CC. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990;141:914-921.
315. Redding GJ, Restuccia R, Cotton EK, Brooks JG. Serial changes in pulmonary functions in children hospitalized with cystic fibrosis. Am Rev Respir Dis 1982;126:31-36.
316. Smith AL, Redding G, Doershuk C, Goldmann D, Gore E, Hilman B, Marks M, Moss R, Ramsey B, Rubio T. Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. J Pediatr 1988;112:547-554.
317. Orenstein DM, Pattishall EN, Nixon PA, Ross EA, Kaplan RM. Quality of well-being before and after antibiotic treatment of pulmonary exacerbation in patients with cystic fibrosis. Chest 1990;98:1081-1084.
318. Noone PG, Knowles M. Standard therapy of CF lung disease. In: Yankaskas J, Knowles M, editors. Cystic fibrosis in adults. Philadelphia, PA: Lippincott-Raven; 1999. p. 145-175.
319. Saiman L, Chen Y, Tabibi S, Gabriel PS, Zhou J, Liu Z, Lai L, Whittier S. Identification and antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from patients with cystic fibrosis. J Clin Microbiol 2001;39:3942-3945.
320. Saiman L, Mehar F, Niu WW, Neu HC, Shaw KJ, Miller G, Prince A. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis 1996;23:532-537.
321. de Groot R, Smith A. Antibiotic pharmacokinetics in cystic fibrosis: differences and clinical significance. Clin Pharmacokinet 1987;13:228-253.
322. Prandota J. Drug disposition in cystic fibrosis: progress in understanding pathophysiology and pharmacokinetics. Pediatr Infect Dis J 1987;6: 1111-1126.
323. Kearns GL, Trang JM. Introduction to pharmacokinetics: aminoglycosides in cystic fibrosis as a prototype. J Pediatr 1986;108:847-853.
324. Vie P, Ategbo S, Turck D, Husson MO, Tassin E, Loeuille GA, Deschildre A, Druon D, Elian JC, Arrouet-Lagandre C, et al. Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients. Eur J Pediatr 1996;155:948-953.
325. Bates RD, Nahata MC, Jones JW, McCoy K, Young G, Cox S, Barson WJ. Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis. Chest 1997;112:1208-1213.
326. Master V, Roberts GW, Coulthard KP, Baghurst PA, Martin A, Roberts ME, Onishko CR, Martin AJ, Linke RJ, Holmes M, et al. Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study. Pediatr Pulmonol 2001;31: 367-376.
327. Beringer PM, Vinks AA, Jelliffe RW, Shapiro BJ. Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration. Antimicrob Agents Chemother 2000;44:809-813.
328. Reed MD, Spino M. Clinical pharmacokinetics: concepts to practice. In: Orenstein DM, Stern RC, editors. Treatment of the hospitalized cystic fibrosis patient. New York: Marcel Dekker, Inc.; 1998. p. 301-355.
329. Cystic Fibrosis Foundation [CFF]. Consensus Conference: Use of Aerosolized Antibiotics in CF Patients. Bethesda, MD: Cystic Fibrosis Foundation; 1997.
330. Moore RA, Hancock RE. Involvement of outer membrane of Pseudomonas cepacia in aminoglycoside and polymyxin resistance. Antimicrob Agents Chemother 1986;30:923-926.
331. Aaron SD, Ferris W, Henry DA, Speert DP, Macdonald NE. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med 2000;161:1206-1212.
332. Lewin C, Doherty C, Govan J. In vitro activities of meropenem, PD 127391, PD 131628, ceftazidime, chloramphenicol, co-trimoxazole, and ciprofloxacin against Pseudomonas cepacia. Antimicrob Agents Chemother 1993;37:123-125.
333. Burns J, Saiman L. Burkholderia cepacia infections in cystic fibrosis. Pediatr Infect Dis J 1999;18:155-156.
334. Krueger TS, Clark EA, Nix DE. In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations. Diagn Microbiol Infect Dis 2001;41:71-78.
335. Sanyal SC, Mokaddas EM. The increase in carbapenem use and emergence of Stenotrophomonas maltophilia as an important nosocomial pathogen. J Chemother 1999;11:28-33.
336. Ebert DL, Oliver KN. Nontuberculous mycobacteria in the setting of cystic fibrosis. Clin Chest Med 2002;23:655-663.
337. Ada G. Advances in immunology: vaccines and vaccination. N Engl J Med 2001;345:1042-1053.
338. Bryan LE, Kureishi A, Rabin HR. Detection of antibodies to Pseudomonas aeruginosa alginate extracellular polysaccharide in animals and cystic fibrosis patients by enzyme-linked immunosorbent assay. J Clin Microbiol 1983;18:276-282.
339. Bruderer U, Cryz SJ Jr, Schaad UB, Deusinger M, Que JU, Lang AB. Affinity constants of naturally acquired and vaccine-induced anti-Pseudomonas aeruginosa antibodies in healthy adults and cystic fibrosis patients. J Infect Dis 1992;166:344-349.
340. Langford DT, Hiller J. Prospective, controlled study of a polyvalent pseudomonas vaccine in cystic fibrosis: three year results. Arch Dis Child 1984;59:1131-1134.
341. Cryz SJ Jr, Wedgwood J, Lang AB, Ruedeberg A, Que JU, Furer E, Schaad UB. Immunization of noncolonized cystic fibrosis patients against Pseudomonas
342. Lang AB, Schaad UB, Rudeberg A, Wedgwood J, Que JU, Furer E, Cryz SJ Jr. Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis. J Pediatr 1995;127:711-717.
343. Doring G, Dorner F. A multicenter vaccine trial using the Pseudomonas aeruginosa flagella vaccine IMMUNO in patients with cystic fibrosis. Behring Inst Mitt 1997:338-344.
344. Cryz SJ Jr, Furer E, Que JU. Synthesis and characterization of a Pseudomonas aeruginosa alginate-toxin a conjugate vaccine. Infect Immun 1991;59:45-50.
345. Pickering L, editor. 2000 Red book: report of the committee on infectious diseases, 25th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2000.
346. Saiman L, Siegel J. Cystic Fibrosis Foundation Consensus Conference on Infection Control Participants: infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Am J Infect Control 2003;31:S1-S62.
347. LiPuma JJ, Dasen SE, Nielson DW, Stern RC, Stall TL. Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis. Lancet 1990;336:1094-1096.
348. Govan JR, Brown PH, Maddison J, Doherty CJ, Nelson JW, Dodd M, Greening AP, Webb AK. Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet 1993;342:15-19.
349. Doring G, Jansen S, Noll H, Grupp H, Frank F, Botzenhart K, Magdorf K, Wahn U. Distribution and transmission of Pseudomonas aeruginosa and Burkholderia cepacia in a hospital ward. Pediatr Pulmonol 1996;21: 90-100.
350. Pegues DA, Carson LA, Tablan OC, FitzSimmon SC, Roman SB, Miller JM, Jarvis WR. Acquisition of Pseudomonas cepacia at summer camps for patients with cystic fibrosis. J Pediatr 1994;124:694-702.
351. Mahenthiralingam E, Simpson DA, Speert DP. Identification and characterization of a novel DNA marker associated with epidemic Burkholderia cepacia strains recovered from patients with cystic fibrosis. J Clin Microbiol 1997;35:808-816.
352. Thomassen MJ, Demko CA, Doershuk CF, Stern RC, Klinger JD. Pseudomonas cepacia: decrease in colonization in patients with cystic fibrosis. Am Rev Respir Dis 1986;134:669-671.
353. Pegues DA, Schidlow DV, Tablan OC, Carson LA, Clark NC, Jarvis WR. Possible nosocomial transmission of Pseudomonas cepacia in patients with cystic fibrosis. Arch Pediatr Adolesc Med 1994;148:805-812.
354. Tablan OC, Martone WJ, Doershuk CF, Stern RC, Thomassen MJ, Klinger JD, White JW, Carson LA, Jarvis WR. Colonization of the respiratory tract with Pseudomonas cepacia in cystic fibrosis: risk factors and outcomes. Chest 1987;91:527-532.
355. Reboli AC, Koshinski R, Arias K, Marks-Austin KA, Stieritz D, Stall TL. An outbreak of Burkholderia cepacia lower respiratory tract infection associated with contaminated albuterol nebulization solution. Infect Control Hosp Epidemiol 1996;17:741-743.
356. LiPuma JJ, Spilker T, Coenye T, Gonzalez CF. An epidemic Burkholderia cepacia complex strain identified in soil. Lancet 2002;359:2002-2003.
357. Drabick JA, Gracely EJ, Heidecker GJ, LiPuma JJ. Survival of Burkholderia cepacia on environmental surfaces. J Hosp Infect 1996;32:267-276.
358. Chen JS, Witzmann KA, Spilker T, Fink RJ, LiPuma JJ. Endemicity and inter-city spread of Burkholderia cepacia genomovar III in cystic fibrosis. J Pediatr 2001;139:643-649.
359. Paul ML, Pegler MA, Benn RA. Molecular epidemiology of Burkholderia cepacia in two Australian cystic fibrosis centres. J Hosp Infect 1998;38:19-26.
360. Whiteford ML, Wilkinson JD, McColl JH, Conlon FM, Michie JR, Evans TJ. Outcome of Burkholderia (Pseudomonas) cepacia colonisation in children with cystic fibrosis following a hospital outbreak. Thorax 1995;50:1194-1198.
361. Fung S, Dick H, Devlin R, Tullis DE. Transmissability and infection control implications of Burkholderia cepacia in cystic fibrosis. Can J Infect Dis 1998;9:177-182.
362. Speert DP, Campbell M. Hospital epidemiology of Pseudomonas aeruginosa from patients with cystic fibrosis. J Hosp Infect 1987;9:11-21.
363. Pedersen SS, Koch C, Hoiby N, Rosendal K. An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre. J Antimicrob Chemother 1986;17:505-516.
364. Cheng K, Smyth RL, Govan JR, Doherty C, Winstanley C, Denning N, Heaf DP, van Saene H, Hart CA. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet 1996;348: 639-642.
365. Frederiksen B, Koch C, Hoiby N. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995). Pediatr Pulmonol 1999;28:159-166.
366. Zimakoff J, Hoiby N, Rosendal K, Guilbert JP. Epidemiology of Pseudomonas aeruginosa infection and the role of contamination of the environment in a cystic fibrosis clinic. J Hosp Infect 1983;4:31-40.
367. McIlwaine MP, Davidson AG. Airway clearance techniques in the treatment of cystic fibrosis. Curr Opin Pulm Med 1996;2:447-451.
368. Braggion C, Cappelletti LM, Cornacchia M, Zanolla L, Mastella G. Short-term effects of three chest physiotherapy regimens in patients hospitalized for pulmonary exacerbations of cystic fibrosis: a crossover randomized study. Pediatr Pulmonol 1995;19:16-22.
369. van der Schans C, Prasad A, Main E. Chest physiotherapy compared to no chest physiotherapy for cystic fibrosis. Cochrane Database Syst Rev 2000:CD001401.
370. Hardy KA. A review of airway clearance: new techniques, indications, and recommendations. Respir Care 1994;39:440-455.
371. McIlwaine PM, Wong LT, Peacock D, Davidson AG. Long-term comparative trial of conventional postural drainage and percussion versus positive expiratory pressure physiotherapy in the treatment of cystic fibrosis. J Pediatr 1997;131:570-574.
372. Konstan MW, Stern RC, Doershuk CF. Efficacy of the Flutter device for airway mucus clearance in patients with cystic fibrosis. J Pediatr 1994;124:689-693.
373. Fink J, Mahlmeister M. High-frequency oscillation of the airway and chest wall. Respir Care 2002;47:797-807.
374. Hansen L, Warwick WJ. High-frequency chest compression system to aid in clearance of mucus from the lung. Biomed Instrum Technol 1990;24:289-294.
375. Oermann CM, Sockrider MM, Giles D, Sontag MK, Accurso F, Castile R. Comparison of high-frequency chest wall oscillation and oscillating positive expiratory pressure in the home management of cystic fibrosis: a pilot study. Pediatr Pulmonol 2001;32:372-377.
376. Homnick DN, White F, de Castro C. Comparison of effects of an intrapulmonary percussive ventilator to standard aerosol and chest physiotherapy in treatment of cystic fibrosis. Pediatr Pulmonol 1995;20:50-55.
377. Gondor M, Nixon PA, Mutich R, Rebovich P, Orenstein D. Comparison of flutter device and chest physical therapy in the treatment of cystic fibrosis pulmonary exacerbation. Pediatr Pulmonol 1999;28:255-260.
378. App EM, Kieselmann R, Reinhardt D, Lindermann H, Dasgupta B, King M, Brand PL. Sputum rheology changes in cystic fibrosis lung disease. Chest 1998;114:171-177.
379. McCoy K, Hamilton S, Johnson C. Pulmozyme Study Group: effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Chest 1996;110:889-895.
380. Quan JM, Tiddens HA, Sy JP, McKenzie SG, Montgomery MD, Robinson PJ, Wohl ME, Konstan MW. The Pulmozyme Early Intervention Trial Study Group: a two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001;139:813-820.
381. Robinson PJ. Dornase alfa in early cystic fibrosis lung disease. Pediatr Pulmonol 2002;34:237-241.
382. Wagener JS, Rock MJ, McCubbin MM, Hamilton SD, Johnson CA, Ahrens RC. Pulmozyme Pediatric Broncoscopy Study Group: aerosol delivery and safety of recombinant human deoxyribonuclease in young children with cystic fibrosis: a bronchoscopic study. J Pediatr 1998;133: 486-491.
383. Eisenberg JD, Aitken ML, Dorkin HL, Harwood IR, Ramsey BW, Schidlow DV, Wilmott RW, Wohl ME, Fuchs HJ, Christiansen DH, et al. Safety of repeated intermittent courses of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. J Pediatr 1997;131:118-124.
384. King M, Dasgupta B, Tomkiewicz RP, Brown NE. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I. Am J Respir Crit Care Med 1997;156:173-177.
385. Robinson M, Regnis JA, Bailey DL, King M, Bautovich GJ, Bye PT. Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. Am J Respir Crit Care Med 1996;153:1503-1509.
386. Robinson M, Hemming AL, Regnis JA, Wong AG, Bailey DL, Bautovich GJ, King M, Bye PT. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 1997;52:900-903.
387. Rodwell LT, Anderson SD. Airway responsiveness to hyperosmolar saline challenge in cystic fibrosis: a pilot study. Pediatr Pulmonol 1996;21:282-289.
388. Eng PA, Morton J, Douglass JA, Riedler J, Wilson J, Robertson CF. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatr Pulmonol 1996;21:77-83.
389. Wark PA, McDonald V. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev 2003:CD001506.
390. Mitchell I, Corey M, Woenne R, Krastins IR, Levison H. Bronchial hyperreactivity in cystic fibrosis and asthma. J Pediatr 1978;93:744-748.
391. Weinberger M. Airways reactivity in patients with CF. Clin Rev Allergy Immunol 2002;23:77-85.
392. Brand PL. Bronchodilators in cystic fibrosis. J R Soc Med 2000;93:37-39.
393. Hordvik NL, Sammut PH, Judy CG, Strizek SJ, Colombo JL. The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. Am J Respir Crit Care Med 1996;154:156-160.
394. Konig P, Gayer D, Barbero GJ, Shaffer J. Short-term and long-term effects of albuterol aerosol therapy in cystic fibrosis: a preliminary report. Pediatr Pulmonol 1995;20:205-214.
395. Hordvik NL, Konig P, Morris D, Kreutz C, Barbero GJ. A longitudinal study of bronchodilator responsiveness in cystic fibrosis. Am Rev Respir Dis 1985;131:889-893.
396. Hordvik NL, Sammut PH, Judy CG, Colombo JL. Effectiveness and tolerability of high-dose salmeterol in cystic fibrosis. Pediatr Pulmonol 2002;34:287-296.
397. Sanchez I, De Koster J, Holbrow J, Chernick V. The effect of high doses of inhaled salbutamol and ipratropium bromide in patients with stable cystic fibrosis. Chest 1993;104:842-846.
398. Weintraub SJ, Eschenbacher WL. The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. Chest 1989;95:861-864.
399. Ziebach R, Breitfeld-Pietsch B, Sichler M, Busch A, Riethmuller J, Stem M. Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: double-blind, placebo controlled crossover study in cystic fibrosis. Pediatr Pulmonol 2001;31:431-435.
400. Fink JB. Aerosol device selection: evidence to practice. Respir Care 2000;45:874-885.
401. Coakley AL. Helping patients to master correct inhaler techniques: nursing role. Br J Nurs 2001;10:424.
402. Terzano C. Metered dose inhalers and spacer devices. Eur Rev Med Pharmacol Sci 1999;3:159-169.
403. Rosenfeld M, Joy P, Nguyen CD, Krzewinski J, Burns JL. Cleaning home nebulizers used by patients with cystic fibrosis: is rinsing with tap water enough? J Hosp Infect 2001;49:229-230.
404. Auerbach HS, Williams M, Kirkpatrick JA, Colten HR. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 1985;2:686-688.
405. Eigen H, Rosenstein BJ, FitzSimmons S, Schidlow DV. Cystic Fibrosis Foundation Prednisone Trial Group: a multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. J Pediatr 1995; 126:515-523.
406. Davis PB, Kercsmar CM. Growth in children with chronic lung disease. N Engl J Med 2000;342:887-888.
407. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995;332:848-854.
408. Oermann CM, Sockrider MM, Konstan MW. The use of anti-inflammatory medications in cystic fibrosis: trends and physician attitudes. Chest 1999;115:1053-1058.
409. Konstan MW, Butler SM, Schidlow DV, Morgan WJ, Julius JR, Johnson CA. Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis: patterns of medical practice in cystic fibrosis. Part II: use of therapies. Pediatr Pulmanol 1999;28:248-254.
410. van Haren EH, Lammers JW, Festen J, Heijerman HG, Groot CA, van Herwaarden CL. The effects of the inhaled corticosteroid budesonide on lung function and bronchial hyperresponsiveness in adult patients with cystic fibrosis. Respir Med 1995;89:209-214.
411. Nikolaizik WH, Schoni MH. Pilot study to assess the effect of inhaled corticosteroids on lung function in patients with cystic fibrosis. J Pediatr 1996;128:271-274.
412. Bisgaard H, Pedersen SS, Nielsen KG, Skov M, Laursen EM, Kronborg G, Reimert CM, Hoiby N, Koch C. Controlled trial of inhaled budesonide in patients with cystic fibrosis and chronic bronchopulmonary Psuedomonas aeruginosa infection. Am J Respir Crit Care Med 1997; 156:1190-1196.
413. Balfour-Lynn IM, Klein NJ, Dinwiddie R. Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis. Arch Dis Child 1997;77:124-130.
414. Wojtczak HA, Kerby GS, Wagener JS, Copenhaver SC, Gotlin RW, Riches DW, Accurso FJ. Beclomethasone diproprionate reduced airway inflammation without adrenal suppression in young children with cystic fibrosis: a pilot study. Pediatr Pulmonol 2001;32:293-302.
415. Schmitt-Grobe S, Eickmeier O, Schubert R, Bez C, Zielen S. Anti-inflammatory effects of montelukast in mild cystic fibrosis. Ann Allergy Asthma Immunol 2002;89:599-605.
416. McElvaney NG, Nakamura H, Birrer P, Hebert CA, Wong WL, Alphonse M, Baker JB, Catalano MA, Crystal RG. Modulation of airway inflammation in cystic fibrosis: in vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest 1992;90:1296-1301.
417. McElvaney NG, Hubbard RC, Birrer P, Chernick MS, Caplan DB, Frank MM, Crystal RG. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet 1991;337:392-394.
418. Roum JH, Borok Z, McElvaney NG, Grimes GJ, Bokser AD, Buhl R, Crystal RG. Glutathione aerosol suppresses lung epithelial surface inflammatory cell-derived oxidants in cystic fiborsis. J Appl Physiol 1999;87:438.
419. Snyder AH, McPherson ME, Hunt JF, Johnson M, Stamler JS, Gaston B. Acute effects of aerosolized S-nitrosoglutathione in cystic fibrosis. Am J Respir Crit Care Med 2002;165:922-926.
420. Stevens DA, Schwarte HJ, Lee JY, Moskovitz BL, Jerome DC, Catanzaro A, Bamberger DM, Weinmann AJ, Tuazon CU, Judson MA, et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergfflosis. N Engl J Med 2000;342:756-762.
421. Wark PA, Hensley MJ, Saltos N, Boyle MJ, Toneguzzi RC, Epid GD, Simpson JL, McElduff P, Gibson PG. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. J Allergy Clin Immunol 2003;111:952-957.
422. Nepomuceno IB, Esrig S, Moss RB. Allergic bronchopulmonary aspergillosis in cystic fibrosis: role of atopy and response to itraconazole. Chest 1999;115:364-370.
423. Mroueh S, Spock A. Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Chest 1994;105:32-36.
424. Patterson R, Greenberger PA, Halwig JM, Liotta JL, Roberts M. Allergic bronchopulmonary aspergillosis: natural history and classification of early disease by serologic and roentgenographic studies. Arch Intern Med 1986;146:916-918.
425. Marchant JL, Warner JO, Bush A. Rise in total IgE as an indicator of allergic bronchopulmonary aspergillosis in cystic fibrosis. Thorax 1994;49:1002-4005.
426. Leon EE, Craig TJ. Antifungals in the treatment of allergic bronchopulmonary aspergillosis. Ann Allergy Asthma Immunol 1999;82:511-516.
427. Denning DW, Van Wye J, Lewiston N, Stevens DA. Adjunctive therapy of allergic bronchopulmonary aspergillosis with itraconazole. Chest 1991;100:813-819.
428. Rich DP, Anderson MP, Gregory RJ, Cheng SH, Paul S, Jefferson DM, McCann JD, Klinger KW, Smith AE, Welsh MJ. Expression of cystic fibrosis transmembrane conductance regulator corrects defective chloride channel regulation in cystic fibrosis airway epithelial cells. Nature 1990;347:358-363.
429. Drumm ML, Pope HA, Cliff WH, Rommens JM, Marvin SA, Tsui LC, Collins FS, Frizzell RA, Wilson JM. Correction of the cystic fibrosis defect in vitro by retrovirus-mediated gene transfer. Cell 1990;62:1227-1233.
430. Engelhardt JF, Yankaskas J, Ernst SA, Yang Y, Marino CR, Boucher R, Cohn JA, Wilson JM. Submucosal glands are the predominant site of CFTR expression in the human bronchus. Nat Genet 1992;2:240-248.
431. Tizzano EF, Chitayat D, Buchwald M. Cell-specific localization of CFTR mRNA shows developmentally regulated expression in human fetal tissues. Hum Mol Genet 1993;2:219-224.
432. Johnson LG, Olsen JC, Sarkadi B, Moore KL, Swanstrom R, Boucher R. Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat Genet 1992;2:21-25.
433. Johnson LG, Boyles SE, Wilson J, Boucher RC. Normalization of raised sodium absorption and raised calcium-mediated chloride secretion by adenovirus-mediated expression of cystic fibrosis transmembrane conductance regulator in primary human cystic fibrosis airway epithelial cells. J Clin Invest 1995;95:1377-1382.
434. Zabner J, Couture LA, Gregory RJ, Graham SM, Smith AE, Welsh MJ. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 1993;75:207-216.
435. Crystal RG, McElvaney NG, Rosenfeld MA, Chu CS, Mastrangeli A, Hay JG, Brody SL, Jaffe HA, Eissa NT, Danel C. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 1994;8:42-51.
436. Bellon G, Michel-Calemard L, Thouvenot D, Jagneaux V, Poitevin F, Malcus C, Accart N, Layani MP, Aymard M, Bernon H, et al. Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a phase I clinical trial. Hum Gene Ther 1997;8:15-25.
437. Porteous DJ, Dorin JR, McLachlan G, Davidson-Smith H, Davidson H, Stevenson BJ, Carothers AD, Wallace WA, Moralee S, Hoenes C, et al. Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther 1997;4:210-218.
438. Alton EW, Stern M, Farley R, Jaffe A, Chadwick SL, Phillips J, Davies J, Smith SN, Browning J, Davies MG, et al. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet 1999;353:947-954.
439. Caplen NJ, Alton EW, Middleton PG, Dorin JR, Stevenson BJ, Gao X, Durham SR, Jeffery PK, Hodson ME, Coutelle C. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat Med 1995;139-46.
440. Zabner J, Ramsey BW, Meeker DP, Aitken ML, Balfour RP, Gibson RL, Launspach J, Moscicki RA, Richards SM, Standaert TA. Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. J Clin Invest 1996;97:1504-1511.
441. Knowles MR, Hohneker KW, Zhou Z, Olsen JC, Noah TL, Hu PC, Leigh MW, Engelhardt JF, Edwards LJ, Jones KR. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med 1995;333:823-831.
442. Zabner J, Fasbender A, Moninger TO, Poellinger KA, Welsh MJ. Cellular and molecular barriers to gene transfer by a cationic lipid. J Biol Chem 1995;270:18997-19007.
443. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994;91:4407-4411.
444. Flotte TR, Afione SA, Conrad C, McGrath SA, Solow R, Oka H, Zeitlin PL, Guggino WB, Carter BJ. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc Natl Acad Sci USA 1993;90:10613-10617.
445. Flotte TR. Recombinant adeno-associated virus gene therapy for cystic fibrosis and alpha(1)-antitrypsin deficiency. Chest 2002;121:98S-102S.
446. Aitken ML, Moss RB, Waltz DA, Dovey ME, Tonelli MR, McNamara SC, Gibson RL, Ramsey BW, Carter BJ, Reynolds TC. A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. Hum Gene Ther 2001;12:1907-1916.
447. Wagner JA, Nepomuceno IB, Messner AH, Moran ML, Batson EP, Dimiceli S, Brown BW, Desch JK, Norbash AM, Conrad CK, et al. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum Gene Ther 2002;13:1349-1359.
448. Moss RB, Rodman D, Spencer T, Aitken ML, Zeitlin PL, Waltz D, Milla C, Brody AS, Clancy JP, Ramsey B, et al Repeated AAV2 aerosol-mediated CFTR gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest (In press)
449. Duan D, Yue Y, Yan Z, Yang J, Engelhardt JF. Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J Clin Invest 2000;105:1573-1587.
450. Zabner J, Seiler M, Walters R, Kotin RM, Fulgeras W, Davidson BL, Chiorini JA. Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J Virol 2000;74:3852-3858.
451. Halbert CL, Allen JM, Miller AD. Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors. J Virol 2001; 75:6615-6624.
452. Ostedgaard LS, Zabner J, Vermeer DW, Rokhlina T, Karp PH, Stecenko AA, Randak C, Welsh MJ. CFTR with a partially deleted R domain corrects the cystic fibrosis chloride transport defect in human airway epithelia in vitro and in mouse nasal mucosa in vivo. Proc Natl Acad Sci USA 2002;99:3093-3098.
453. Ostedgaard L, Randak C, Rokhlina T, Karp PH, Vermeer DW, Ashbourne-Excoffon KJ, Welsh MJ. Effects of C-terminal deletions on cystic fibrosis transmembrane conductance regulator function in cystic fibrosis airway epithelia. Proc Natl Acad Sci USA 2003;100:1937-1942.
454. Bedwell DM, Kaenjak A, Benos DJ, Bebok Z, Bubien JK, Hong J, Tousson A, Clancy JP, Sorscher EJ. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med 1997;3:1280-1284.
455. Wilschanski M. A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am J Respir Crit Care Med 2000;161:860-865.
456. Barton-Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 1999;104:375-381.
457. Sato S, Ward CL, Krouse ME, Wine JJ, Kopito RR. Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J Biol Chem 1996;271:635-638.
458. Maitra R, Shaw CM, Stanton BA, Hamilton JW. Increased functional cell surface expression of CFTR and DeltaF508-CFTR by the anthracydine doxombicin. Am J Physiol Cell Physiol 2001;280:C1031-C1037.
459. Rubenstein RC, Egan ME, Zeitlin PL. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. J Clin Invest 1997;100:2457-2465.
460. Brown CR, Hong-Brown LQ, Biwersi J, Verkman AS, Welsh MJ. Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein. Cell Stress Chaperones 1996;1:117-125.
461. Guay-Broder C, Jacobson KA, Barnoy S, Cabantchik ZI, Guggino WB, Zeitlin PL, Turner RJ, Vergara L, Eidelman O, Pollard HB. Al receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine selectively activates chloride efflux from human epithelial and mouse fibroblast cell lines expressing the cystic fibrosis transmembrane regulator delta F508 mutation. Biochemistry (Mosc) 1995;34:9079-9087.
462. Rubenstein RC, Zeitlin PL. A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med 1998;157:484-490.
463. McCarty NA, Standaert TA, Teresi M, Tuthill C, Launspach J, Kelley TJ, Milgram LJ, Hilliard KA, Regelmann WE, Weatherly MR, et al. A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis. Pediatr Pulmonol 2002;33:90-98.
464. Kelley TJ, Al-Nakkash L, Cotton CU, Drumm M. Activation of endogenous delta F508 cystic fibrosis transmembrane conductance regulator by phosphodiesterase inhibition. J Clin Invest 1996;98:513-520.
465. Illek B, Fischer H, Machen TE. Genetic disorders of membrane transport. II: regulation of CFTR by small molecules including HCO3. Am J Physiol 1998;275:G1221-G1226.
466. Galietta LV, Jayaraman S, Verkman AS. Cell-based assay for high-throughput quantitative screening of CFTR chloride transport agonists. Am J Physiol Cell Physiol 2001;281:C1734-C1742.
467. Boucher RC, Cotton CU, Gatzy JT, Knowles MR, Yankaskas JR. Evidence for reduced Cl- and increased Na+ permeability in cystic fibrosis human primary cell cultures. J Physiol 1988;405:77-103.
468. Knowles MR, Church NL, Waltner WE, Yankaskas JR, Gilligan P, King M, Edwards LJ, Helms RW, Boucher RC. A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med 1990;322:1189-1194.
469. App EM, King M, Helfesrieder R, Kohler D, Matthys H. Acute and long-term amiloride inhalation in cystic fibrosis lung disease: a rational approach to cystic fibrosis therapy. Am Rev Respir Dis 1990;141:605-612.
470. Jiang T, Sweeney G, Rudolf MT, Klip A, Traynor-Kaplan A, Tsien RY. Membrane-permeant esters of phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998;273:11017-11024.
471. Egan M, Flotte T, Afione S, Solow R, Zeitlin PL, Carter BJ, Guggino WB. Defective regulation of outwardly rectifying Cl- channels by protein kinase a corrected by insertion of CFTR. Nature 1992358:581-584.
472. Knowles MR, Clarke LL, Boucher RC. Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N Engl J Med 1991;325:533-538.
473. Cuppoletti J, Tewari KP, Sherry AM, Kupert EY, Malinowska DH. ClC-2 Cl- channels in human lung epithelia: activation by arachidonic acid, amidation, and acid-activated omeprazole. Am J Physiol Cell Physiol 2001;281:C46-C54.
474. Noone PG, Hamblett N, Accurso F, Aitken ML, Boyle M, Dovey M, Gibson R, Johnson C, Kellerman D, Konstan MW, et al. Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study. Pediatr Pulmonol 2001;32:122-128.
475. Cole AM, Liao H, Stuchlik O, Tilan J, Pohl J, Ganz T. Cationic polypeptides are required for antibacterial activity of human airway fluid. J Immunol 2002;169:6985-6991.
476. Travis SM, Conway B, Zabner J, Smith J, Anderson AM, Singh PK, Greenberg EP, Welsh MJ. Activity of abundant antimicrobials of the human airway. Am J Respir Crit Care Med 1999;20:872-879.
477. Ganz T. Fatal attraction evaded: how pathogenic bacteria resist cationic polypeptides. J Exp Med 2001;193:F31-F34.
478. Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M, Wilson JM. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 1997;88:553-560.
479. Fuchs PC, Barry AL, Brown SD. In vitro antimicrobial activity of MSI-78, a magainin analog. Antimicrob Agents Chemother 1998;42:1213-1216.
480. Ramsey B, Rodman D, Redman R, Haelsen M, Johnson C, Hamblett N, Fujii C, Loury D. Phase I safety and tolerability study of ascending multiple doses of aerosolized iseganan HCL solution (IB-367) in adults with cystic fibrosis. Pediatr Pulmonol 2001;32:A263.
481. Guina T, Yi EC, Wang H, Hackett M, Miller S. A phoP-regulated outer membrane protease of Salmonella enterica serovar typhimurium promotes resistance to alpha-helical antimicrobial peptides. J Bacteriol 2000;182:4077-4086.
482. Guo L, Lim KB, Gunn JS, Bainbridge B, Darveau RP, Hackett M,Miller S. Regulation of lipid a modifications by Salmonella typhimurium virulence genes phoP-phoQ. Science 1997;276:250-253.
483. Zabner J, Seiler M, Launspach J, Karp PH, Kearney WR, Look DC, Smith J, Welsh MJ. The osmolyte xylitol reduces the salt concentration of airway surface liquid and may enhance bacterial killing. Proc Natl Acad Sci USA 2000;97:11614-11619.
484. Uhari M, Kontiokari T, Niemela M. A novel use of xylitol sugar in preventing acute otitis media. Pediatrics 1998;102:879-884.
485. Edgar WM. Sugar substitutes, chewing gum and dental caries: a review. Br Dent J 1998;184:29-32.
486. Feng W, Garrett H, Speert DP, King M. Improved clearability of cystic fibrosis sputum with dextran treatment in vitro. Am J Respir Crit Care Med 1998;157:710-714.
487. Barghouthi S, Guerdoud LM, Speert DP. Inhibition by dextran of Pseudomonas aeruginosa adherence to epithelial cells. Am J Respir Crit Care Med 1996;154:1788-1793.
488. Chiu CH, Wong S, Hancock RE, Speert DP. Adherence of Burkholderia cepacia to respiratory tract epithelial cells and inhibition with dextrans. Microbiol 2001;147:2651-2658.
489. Bryan R, Feldman M, Jawetz SC, Rajan S, DiMango E, Tang HB, Scheffler L, Speert DP, Prince A. The effects of aerosolized dextran in a mouse model of Pseudomonas aeruginosa pulmonary infection. J Infect Dis 1999;179:1449-1458.
490. Tsui L-C, Durie P. Genotype and phenotype in cystic fibrosis. Hosp Pract 1997;32:115-142.